[Form 4] Virios Therapeutics, Inc. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

Iron Mountain Inc. (NYSE: IRM) – Form 144 filing: CEO William L. Meaney has filed a notice of proposed sale for 69,125 common shares through Fidelity Brokerage, with an aggregate market value of roughly $7.05 million. The shares represent only 0.023% of the company’s 295.0 million shares outstanding. The anticipated sale date is 01 July 2025.

The filing shows the shares were acquired via an option granted on 18 Feb 2016 and exercised on 01 July 2025, paid in cash. Meaney has already sold 207,375 shares over the last three months (01 Apr, 02 May, 02 Jun 2025) generating ≈ $19.5 million in gross proceeds. The current notice is therefore a continuation of an ongoing liquidation program, likely under a Rule 10b5-1 trading plan (the form requests plan-adoption date but leaves that field blank).

Because Form 144 is only a notice of intent, the sale may or may not be completed. While insider selling by the CEO can draw investor attention, the percentage of total shares is immaterial and does not directly affect the company’s capital structure or operations. Investors should watch subsequent Form 4 filings to confirm execution and to gauge any larger trend in executive share disposition.

Positive

• None.

Negative

• Continued insider selling by the CEO—total of 276,500 shares over four months—could raise perception concerns despite representing only ~0.09% of shares outstanding.

Insights

Securities Analyst

TL;DR: Minor CEO share sale (0.02% float); signals limited, monitor for cumulative insider trends.

The planned 69,125-share sale equates to roughly one trading day’s volume and will have negligible market-impact on IRM’s float. Because the shares stem from long-dated option exercises, this looks like routine diversification. The three prior equal-sized monthly sales reinforce that narrative. That said, continued insider selling by the CEO can create a negative optics issue if compounded by additional executives. I rate the filing as neutral; valuation and fundamentals remain unchanged.

Corporate Governance Expert

TL;DR: Governance risk low; Rule 144 notice respects disclosure norms.

Meaney’s repeated, evenly spaced sales suggest a pre-arranged Rule 10b5-1 plan, mitigating concerns of trading on undisclosed information. The small stake reduction (<0.1% of his total holdings assuming historical data) does not materially alter alignment between management and shareholders. No adverse governance red flags detected, but investors should verify upcoming Form 4s for compliance with the company’s insider-trading policy.

07/01/2025 - 01:58 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keefer David R

(Last) (First) (Middle)

C/O DOGWOOD THERAPEUTICS, INC.

44 MILTON AVENUE

(Street)

ALPHARETTA GA 30009

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.71	06/27/2025		A		2,362		06/27/2026	06/27/2035	Common Stock	2,362	$0	2,362	D

Explanation of Responses:

	/s/ Greg Duncan, Attorney-in-Fact	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Iron Mountain (IRM) shares does the CEO plan to sell under this Form 144?

The filing covers 69,125 common shares with an estimated market value of $7.05 million.

What percentage of Iron Mountain’s outstanding shares does 69,125 shares represent?

Approximately 0.023% of the total 295,043,896 shares outstanding.

Has the CEO sold IRM shares recently?

Yes. Over the past three months, he sold 207,375 shares for about $19.5 million in gross proceeds.

Does a Form 144 guarantee the sale will occur?

No. Form 144 is a notice of intent; execution is later confirmed via Form 4 after the trade.

What is the expected sale date for the shares?

The approximate sale date listed is 01 July 2025.